Quickmed Biotech And Research Laboratories Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 08-07-2024
- Paid Up Capital ₹ 0.10 M
as on 08-07-2024
- Company Age 12 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.15 M
as on 08-07-2024
- Satisfied Charges ₹ 0.16 M
as on 08-07-2024
- Revenue 112.23%
(FY 2022)
- Profit 339.70%
(FY 2022)
- Ebitda 84.45%
(FY 2022)
- Net Worth 72.36%
(FY 2022)
- Total Assets -20.14%
(FY 2022)
About Quickmed Biotech And Research Laboratories
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.15 M. The company has closed loans amounting to ₹0.16 M, as per Ministry of Corporate Affairs (MCA) records.
Sujeet Kumar and Anand Mohan serve as directors at the Company.
- CIN/LLPIN
U73200UR2012PTC000376
- Company No.
000376
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Aug 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Uttarakhand
Industry
Company Details
- Location
Dehradun, Uttarakhand, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Quickmed Biotech And Research Laboratories?
Board Members(2)
Financial Performance and Corporate Structure Insights of Quickmed Biotech And Research Laboratories.
Quickmed Biotech And Research Laboratories Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 112.23% increase. The company also saw a substantial improvement in profitability, with a 339.7% increase in profit. The company's net worth Soared by an impressive increase of 72.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Quickmed Biotech And Research Laboratories?
In 2016, Quickmed Biotech And Research Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Crisp Lifescience Private Limited
Active
8 years 4 months Sujeet Kumar and Anand Mohan are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 04 Dec 2015 | ₹1.15 M | Open |
Others Creation Date: 01 Jun 2020 | ₹0.16 M | Satisfied |
How Many Employees Work at Quickmed Biotech And Research Laboratories?
Unlock and access historical data on people associated with Quickmed Biotech And Research Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Quickmed Biotech And Research Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Quickmed Biotech And Research Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
